Effect of controlled human Plasmodium falciparum infection on B cell subsets in individuals with different levels of malaria immunity

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Continuous exposure to Plasmodium falciparum (Pf) has been associated with alterations in B cells. We investigated the effect of controlled human malaria infection (CHMI) on B cell phenotypes in individuals with different Pf immunity status: malaria-naïve, immunized with PfSPZ-CVac and semi-immune (lifelong-exposed) volunteers. Compared to naïve, semi-immune but not vaccinated individuals, had increased baseline frequencies of immature B cells (CD19 + CD10 + ), active naive (IgD + CD27 CD21 ) B cells, active atypical (IgD CD27 CD21 ) memory B cells (MBCs), active classical (IgD CD27 + CD21 ) MBCs and CD1c + -B cells but lower frequencies of some IgG + -B cells. The frequencies of CD1c + active atypical MBCs correlated positively with anti-Pf antibodies and negatively with circulating eotaxin levels, while the opposite was observed for IgG + resting atypical MBCs. During early blood-stage infection (day 11 after CHMI), there was an expansion of resting classical (IgD CD27 + CD21 + ) MBCs in all three groups. Vaccination, compared to placebo, altered the effect of CHMI on B cells, showing a positive association with resting classical MBCs (β = 0.190, 95%CI 0.011–0.368) and active naïve-PD1 + (β = 0.637, 95%CI 0.058–1.217) frequencies, and a negative one with CD1c + resting atypical MBCs (β=-0.328, 95%CI -0.621–-0.032). In addition, the sickle cell trait in semi-immune subjects altered the effect of CHMI on several B cells. In conclusion, lifelong but not vaccine exposure to malaria was associated with increased frequencies of multiple B cell subsets, with higher and lower percentages of CD1c and IgG expressing-cells, respectively. A single infection (CHMI) induces changes in B cell frequencies and is modulated by sickle cell trait and malaria-immunity status. Clinical Trials Registration. NCT01624961, NCT02115516, and NCT02237586.

Article activity feed